IQVIA Holdings Inc. $IQV Shares Sold by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 70.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,676 shares of the medical research company’s stock after selling 10,904 shares during the period. J. Safra Sarasin Holding AG’s holdings in IQVIA were worth $888,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in IQV. Versant Capital Management Inc boosted its stake in shares of IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after acquiring an additional 53 shares in the last quarter. Private Trust Co. NA boosted its position in IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after purchasing an additional 67 shares in the last quarter. CVA Family Office LLC grew its holdings in IQVIA by 11.6% in the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 68 shares during the last quarter. E Fund Management Co. Ltd. increased its position in shares of IQVIA by 3.7% in the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after buying an additional 74 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its stake in shares of IQVIA by 2.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock worth $531,000 after buying an additional 78 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. UBS Group increased their price objective on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Barclays set a $230.00 price objective on IQVIA in a research report on Monday, December 15th. Robert W. Baird set a $258.00 target price on IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. Finally, Citigroup boosted their price target on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $251.06.

IQVIA Stock Down 0.6%

IQV stock opened at $239.67 on Thursday. The company has a 50 day moving average price of $230.48 and a two-hundred day moving average price of $207.51. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a market capitalization of $40.82 billion, a P/E ratio of 32.88, a PEG ratio of 2.45 and a beta of 1.36. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.84 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.